Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Michael_A._Sherman
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
oncology
antiviral therapeutics |
| gptkbp:formerName |
gptkb:Chimerix,_Inc.
|
| gptkbp:founded |
2000
|
| gptkbp:headquartersLocation |
gptkb:Durham,_North_Carolina,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Chimerix
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:Tembexa
|
| gptkbp:product |
Tembexa (brincidofovir)
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:tradedOn |
gptkb:NASDAQ:CMRX
|
| gptkbp:website |
https://www.chimerix.com/
|
| gptkbp:bfsParent |
gptkb:Ernest_Mario
|
| gptkbp:bfsLayer |
6
|